http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b5f85d801dcf389a6acae1e1fc4af2c6
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Taplin |
| name | Mary-Ellen Taplin |
| given-name | Mary-Ellen |
| organization-name | Dana-Farber Cancer Institute, Boston, MA Ethan Basch, Ronald C. Chen, and Stacie B. Dusetzina, University of North Carolina, Chapel Hill; Derek Raghavan, Carolinas Health Care/Levine Cancer Institute, Charlotte, NC; D. Andrew Loblaw, Odette Cancer Centre, Sunnybrook Health Sciences Centre; Ted Wootton, Patient Representatives, Toronto; Sebastian Hotte and Cindy Walker-Dilks, McMaster University; Cindy Walker-Dilks, Cancer Care Ontario, Hamilton; Eric Winquist, London Health Sciences Centre, London, Ontario; Fred Saad, University of Montreal,... 4Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. 1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. 2Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Authors' Affiliations: 1Genitourinary Medical Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California; 2MD Anderson Cancer Center, Houston, Texas; 3Division of Hematology-Oncology, Massachusetts General Hospital; 4Dana-Farber Cancer Institute; 5Beth Israel Deaconess Medical Center, Boston, Massachusetts; and 6Ortho Biotech Oncology Research and Development, a Unit of Cougar Biotechnology, Los Angeles, California 7Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Dana-Farber Cancer Institute, Boston, MA, United States. Maria I. Carlo and Wassim Abida, Memorial Sloan-Kettering Cancer Center; Himisha Beltran, Weill Cornell Medical Center; Jacob Vinson, Prostate Cancer Clinical Trials Consortium, New York, NY; Veda N. Giri, Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA; Channing J. Paller and Emmanuel S. Antonarakis, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Joshi J. Alumkal and Tomasz M. Beer, Oregon Health & Science University, Portland, OR; Daniel J. George... Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA Dana-Farber/Partners Cancer Care, Harvard Medical School, Boston, MA. Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA. Lank Center of Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States 6Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Genitourinary Oncology, Dana Farber Cancer Center, Boston, MA Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School and the Beth Israel Deaconess Medical Center, Boston, Massachusetts Toni K. Choueiri, Susanna Jacobus, Joaquim Bellmunt, Angela Qu, Edward C. Stack, Sabina Signoretti, Meghara Walsh, Graeme Steele, Michelle Hirsch, Christopher J. Sweeney, Mary-Ellen Taplin, Adam S. Kibel, Katherine M. Krajewski, Philip W. Kantoff, Robert W. Ross, and Jonathan E. Rosenberg, Dana-Farber Cancer Institute and Brigham and Women's Hospital; Christopher Tretter, Lahey Clinic, Burlington; Glenn J. Bubley, Beth Israel Deaconess Medical Center, Boston, MA; Leonard J. Appleman, University of... 5Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 2Dana-Farber Cancer Institute, Boston, Massachusetts. Department of Medical Oncology, Dana-Farber/Partners Cancer Care, Boston, MA Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Gerhardt Attard, The Institute of Cancer Research and the Royal Marsden National Health Service Foundation Trust, London, United Kingdom; Michael Borre, Aarhus University Hospital, Aarhus, Denmark; Howard Gurney, Macquarie University, Sydney, New South Wales, Australia; Yohann Loriot, Gustave Roussy, Institut National de la Santé et de la Recherche Médicale U981, University of Paris Saclay, Villejuif, France; Corina Andresen-Daniil, Ranjith Kalleda, and Trinh Pham, Pfizer, New York, NY; and Mary-Ellen... 6Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Toni K. Choueiri, Robert W. Ross, Susanna Jacobus, Stephanie C. Morrissey, Geoffrey C. Buckle, Mary-Ellen Taplin, Jonathan E. Rosenberg, and Philip W. Kantoff, Dana-Farber Cancer Institute; Glenn J. Bubley, Beth Israel Deaconess Medical Center, Boston, MA; Ulka Vaishampayan, Karmanos Cancer Institute, Detroit, MI; Evan Y. Yu, Seattle Cancer Care Alliance/University of Washington, Seattle, WA; David I. Quinn, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA; Noah M.... 7Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. 2Harvard Medical School University, Boston, Massachusetts.; 5Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Authors' Affiliations: 1Dana-Farber Cancer Institute; 2Harvard Medical School; 3Dana-Farber/Harvard Cancer Center; 4Beth Israel Deaconess Medical Center, Boston, Massachusetts; 5Department of Defense Prostate Cancer Clinical Trials Consortium, New York, NY; 6Sunnybrook Health Science Centre, Toronto, Ontario, Canada; 7Oregon Health and Science University, Knight Cancer Institute, Portland, Oregon; 8M. D. Anderson Cancer Center, Houston, Texas; 9Johns Hopkins University School of Medicine, Baltimore, Maryland; 10Tulane Cancer Center, New Orleans, Louisiana; and 11GlaxoSmithKline, Research Triangle Park, North Carolina; Authors' Affiliations: 1Dana-Farber Cancer Institute; 2Harvard Medical School; 3Dana-Farber/Harvard Cancer Center; 4Beth Israel Deaconess Medical Center, Boston, Massachusetts; 5Department of Defense Prostate Cancer Clinical Trials Consortium, New York, NY; 6Sunnybrook Health Science Centre, Toronto, Ontario, Canada; 7Oregon Health and Science University, Knight Cancer Institute, Portland, Oregon; 8M. D. Anderson Cancer Center, Houston, Texas; 9Johns Hopkins University School of Medicine, Baltimore, Maryland; 10Tulane Cancer Center, New Orleans, Louisiana; and 11GlaxoSmithKline, Research Triangle Park, North Carolina; Authors' Affiliations: 1Dana-Farber Cancer Institute; 2Harvard Medical School; 3Dana-Farber/Harvard Cancer Center; 4Beth Israel Deaconess Medical Center, Boston, Massachusetts; 5Department of Defense Prostate Cancer Clinical Trials Consortium, New York, NY; 6Sunnybrook Health Science Centre, Toronto, Ontario, Canada; 7Oregon Health and Science University, Knight Cancer Institute, Portland, Oregon; 8M. D. Anderson Cancer Center, Houston, Texas; 9Johns Hopkins University School of Medicine, Baltimore, Maryland; 10Tulane Cancer Center, New Orleans, Louisiana; and 11GlaxoSmithKline, Research Triangle Park, North Carolina; Authors' Affiliations: 1Dana-Farber Cancer Institute; 2Harvard Medical School; 3Dana-Farber/Harvard Cancer Center; 4Beth Israel Deaconess Medical Center, Boston, Massachusetts; 5Department of Defense Prostate Cancer Clinical Trials Consortium, New York, NY; 6Sunnybrook Health Science Centre, Toronto, Ontario, Canada; 7Oregon Health and Science University, Knight Cancer Institute, Portland, Oregon; 8M. D. Anderson Cancer Center, Houston, Texas; 9Johns Hopkins University School of Medicine, Baltimore, Maryland; 10Tulane Cancer Center, New Orleans, Louisiana; and 11GlaxoSmithKline, Research Triangle Park, North Carolina From the Department of Medicine, Joan and Sanford E. Weill College of Medicine of Cornell University, Ithaca; Clinical Laboratories, Department of Radiology, and Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY; Cancer Research United Kingdom Centre for Cancer Therapeutics, Institute of Cancer Research, Royal Marsden Hospital, London, United Kingdom; University of California-San Francisco Comprehensive Cancer Center, San Francisco; Department of... From the Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Harvard Medical School, Boston; University of Massachusetts Memorial Medical Center, Worcester, MA; and Dartmouth Hitchcock Medical Center, Lebanon, NH Lank Center of Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts University of Massachusetts Memorial Health Center, Department of Oncology, 55 Lake Ave North, Worcester, MA 01655, USA. taplinm@ummhc.org. 3Dana-Farber/Harvard Cancer Center, Boston, Massachusetts. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts From the Division of Oncology, University of Utah/Huntsman Cancer Institute, Salt Lake City, UT; Division of Oncology, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Division of Hematology/Oncology, University of California-San Francisco, Helen Diller Comprehensive Cancer Center, San Francisco, CA. 5Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Ming Yang, Wanling Xie, Mari Nakabayashi, Lillian Werner, Tong Sun, Mark Pomerantz, Matthew Freedman, Robert Ross, Meredith Regan, Myles Brown, Mary-Ellen Taplin, Gwo-Shu Mary Lee, Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School; Steven Balk, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Elahe Mostaghe, University of Washington, Seattle, WA; Nima Sharifi, University of Texas South-western Medical Center, Dallas, TX; William Douglas Figg, National Cancer... Katherine S. Virgo, Emory University, Atlanta, GA; Ethan Basch, University of North Carolina, Chapel Hill, NC; D. Andrew Loblaw, Sunnybrook Health Sciences Centre, Toronto; Eric Winquist, London Health Sciences Centre, London, Ontario, Canada; Thomas K. Oliver and R. Bryan Rumble, American Society of Clinical Oncology, Alexandria, VA; Michael A. Carducci, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Luke Nordquist, Urology Cancer Center and GU Research Network, Omaha,... 7Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. 7Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York New York. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. 3Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, MA, USA Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA; Harvard Medical School, Boston, Massachusetts 02115, USA Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215; 5Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Mary-Ellen Taplin, Massimo Loda, Rosina T. Lis, Wanling Xie, Zhenyang Jiang, and Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School; Glenn J. Bubley, Huihui Ye, and Steven P. Balk, Beth Israel Deaconess Medical Center; Jerome P. Richie, Massimo Loda, and Rosina T. Lis, Brigham and Women's Hospital, Boston, MA; Bruce Montgomery, Bruce L. Dalkin, Lawrence D. True, and Alvin M. Matsumoto, University of Washington; Brett T. Marck and Alvin M. Matsumoto, Geriatric Research, Education and... 4Dana-Farber Cancer Institute, Boston, Massachusetts. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Rana R. McKay, Lillian Werner, Christopher J. Sweeney, Philip W. Kantoff, and Mary-Ellen Taplin, Dana-Farber Cancer Institute, Boston; Robert W. Ross, Bluebird Bio, Cambridge, MA; Amado J. Zurita and Hai T. Tran, MD Anderson Cancer Center, Houston, TX; Justine Y. Bruce, University of Wisconsin Carbone Cancer Center, Madison, WI; Michael A. Carducci, Johns Hopkins University; Arif Hussain, Greenebaum Cancer Center, Baltimore, MD; Mark N. Stein, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ;... 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; 3Harvard Medical School, Boston, Massachusetts. Dana‐Farber Cancer Institute and Harvard Medical School, Boston, MA Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, MA All authors: Department of Imaging, Dana-Farber Cancer Institute/Brigham and Women’s Hospital, Harvard Medical School, 450 Brookline Ave, Boston, MA 02115. G. Celine Han, Justin Hwang, Stephanie A.M. Wankowicz, Zhenwei Zhang, David Liu, Scott L. Carter, William C. Hahn, Mary-Ellen Taplin, and Eliezer M. Van Allen, Dana-Farber Cancer Institute; Glenn C. Gaviola, Varand Ghazikhanian, William C. Hahn, and Eliezer M. Van Allen, Brigham and Women’s Hospital; Glenn J. Bubley and Steven P. Balk, Beth Israel Deaconess Medical Center, Boston; G. Celine Han, Justin Hwang, Stephanie A.M. Wankowicz, David Liu, Carrie Cibulskis, Scott L. Carter, William C. Hahn, and... From the Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 12Dana-Farber Cancer Institute, Boston, Massachusetts. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. 1Dana-Farber Cancer Institute, Boston, Massachusetts. 12Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Dana-Farber/Partners CancerCare, Boston, MA Dana-Farber Cancer Institute, Boston, Massachusetts Dana Farber Cancer Institute, Harvard Medical School, 1230 Dana Building, 44 Binney Street, Boston, MA 02115, USA |
Incoming Links
Total number of triples: 237.